JP2022532877A5 - - Google Patents

Info

Publication number
JP2022532877A5
JP2022532877A5 JP2021566284A JP2021566284A JP2022532877A5 JP 2022532877 A5 JP2022532877 A5 JP 2022532877A5 JP 2021566284 A JP2021566284 A JP 2021566284A JP 2021566284 A JP2021566284 A JP 2021566284A JP 2022532877 A5 JP2022532877 A5 JP 2022532877A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566284A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532877A (ja
JP7617030B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/031925 external-priority patent/WO2020227563A1/en
Publication of JP2022532877A publication Critical patent/JP2022532877A/ja
Publication of JP2022532877A5 publication Critical patent/JP2022532877A5/ja
Application granted granted Critical
Publication of JP7617030B2 publication Critical patent/JP7617030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566284A 2019-05-08 2020-05-07 Jak阻害剤 Active JP7617030B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962845119P 2019-05-08 2019-05-08
US62/845,119 2019-05-08
US201962884588P 2019-08-08 2019-08-08
US62/884,588 2019-08-08
PCT/US2020/031925 WO2020227563A1 (en) 2019-05-08 2020-05-07 Jak inhibitors

Publications (3)

Publication Number Publication Date
JP2022532877A JP2022532877A (ja) 2022-07-20
JP2022532877A5 true JP2022532877A5 (enExample) 2023-05-16
JP7617030B2 JP7617030B2 (ja) 2025-01-17

Family

ID=73051620

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566284A Active JP7617030B2 (ja) 2019-05-08 2020-05-07 Jak阻害剤

Country Status (13)

Country Link
US (1) US11136329B2 (enExample)
EP (1) EP3966209A4 (enExample)
JP (1) JP7617030B2 (enExample)
KR (1) KR102916168B1 (enExample)
CN (1) CN114269734B (enExample)
AU (1) AU2020267661B2 (enExample)
BR (1) BR112021022380A2 (enExample)
CA (1) CA3139277A1 (enExample)
IL (1) IL287876A (enExample)
MX (1) MX2021013602A (enExample)
SG (1) SG11202112362YA (enExample)
TW (1) TWI865525B (enExample)
WO (1) WO2020227563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
CN114644633B (zh) * 2020-12-18 2026-02-03 北京诺诚健华医药科技有限公司 杂环类jak抑制剂
KR102637915B1 (ko) * 2021-06-25 2024-02-19 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ck12抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801971A (zh) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
AU2008211172A1 (en) 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
EA022120B1 (ru) * 2009-10-20 2015-11-30 Целльзом Лимитид Аналоги гетероциклил пиразолопиримидина в качестве ингибиторов jak
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012143320A1 (en) * 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
KR20140063700A (ko) * 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
EA025186B1 (ru) 2012-06-29 2016-11-30 Пфайзер Инк. НОВЫЕ 4-(ЗАМЕЩЕННЫЙ АМИНО)-7Н-ПИРРОЛО[2,3-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LRRK2
BR112017027951A2 (pt) 2015-06-22 2018-08-28 Ono Pharmaceutical Co., Ltd. composto inibitório de brk
CN108864057B (zh) * 2017-05-16 2020-03-31 山东大学 含有4-氨基吡唑结构的jak与hdac双靶点抑制剂及其制备方法和应用
CN114269734B (zh) 2019-05-08 2026-03-27 维玛兰生物科学公司 Jak抑制剂
CA3150281A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
EP4034107A4 (en) 2019-09-25 2023-08-30 Vimalan Biosciences, Inc. JAK INHIBITORS

Similar Documents

Publication Publication Date Title
JP2022519696A5 (enExample)
JP2022529311A5 (enExample)
IL291345B2 (en) Il-17a modulators and uses thereof
JP2024529839A5 (enExample)
JP2024520481A5 (enExample)
JP2022541254A5 (enExample)
JP2022541514A5 (enExample)
JP2016530210A5 (enExample)
JP2021523200A5 (enExample)
JP2013501074A5 (enExample)
JP2024539946A5 (enExample)
JP2021522280A5 (enExample)
JP2024512931A5 (enExample)
JP2020500178A5 (enExample)
CN106459024A (zh) 环丙胺化合物及其用途
JP2010516844A5 (ja) 硬化性接着剤組成物
CN103524440A (zh) 痛风治疗药Lesinurad的制备方法及Lesinurad中间体
JP6306173B2 (ja) ベンズイミダゾール誘導体の製造方法
JP2022552445A5 (enExample)
JP2015535847A5 (enExample)
JP2019510794A5 (enExample)
JP2023513373A5 (enExample)
JP2020535124A5 (enExample)
JP2022509206A5 (enExample)
JP2025502943A5 (enExample)